Galapagos Collaborates With BridGene Biosciences To Develop Cancer Treatments
BridGene Biosciences Announces Strategic Collaboration with Galapagos
BridGene Biosciences to Present Pre-Clinical Data of BGI-9004 at the AACR Annual Meeting 2023
SAN JOSE, Calif., April 6, 2023 /PRNewswire/ -- BridGene Biosciences, Inc., a biotechnology company using a proprietary chemoproteomics technology to discover and develop small molecules for high-value, traditionally undruggable targets, today announced Ping Cao, Ph.D., CEO and co-founder, will give a presentation at the 3rd Annual Ligase Targeting Drug Development Summit on Thursday, April 13, 2023, at 9:00 a.m. ET in Boston, Massachusetts. nnBridGene has developed a highly efficient and unique approach to generate new Protac molecules with improved drug-like properties. Leveraging its live-cell IMTAC™ chemoproteomic platform for identifying small molecules against challenging targets, BridGene has successfully identified covalent ligands for more than 100 E3 ligases. BridGene's specifically designed covalent library has enabled rapid transformation of selected screening hits into fully functional PROTACs through one-step click chemistry. Most E3 ligases are challenging to target due to lack of deep, hydrophobic pockets. Covalent small molecules can bind to them through covalent bond, rendering many more E3 ligases ligandable. This significantly expands the range of targetable E3 ligases. Furthermore, the novel covalent PROTACs developed by BridGene can improve kinetic stability, enhance degradation, and reduce the Hook effect. Most importantly, these new PROTACs have considerably smaller molecule weights and possess more drug-like properties, increasing their likelihood of oral bioavailability and allowing for faster optimization timelines. nnDetails regarding Dr. Cao's presentation are as follows: nnEvent: nn3rd Annual Ligase Targeting Drug Development Summit nnTopic: nnA Chemoproteomic Platform for Identification of Covalent Small Molecule Ligands of Novel E3 Ligases and Rapid Progression Towards Functionally Active and Drug-like PROTACs nnHarnessing the unique advantages of covalent small molecule ligands of E3 ligases nPresenting multiple examples of how IMTACTM-screening can quickly identify covalent small molecule ligands of novel E3 ligases in a live cell nDemonstrating effective protein degradation using PROTACs generated from IMTAC hits through one-step click chemistry nDate: nnApril 13, 2023 nnTime: nn9:00 a.m. ET nnLocation: nnHilton Boston Logan Airport, One Hotel Dr., Boston, Mass. nnAbout BridGene Biosciences nBridGene is a biotechnology company focused on discovering and developing innovative small molecules that drug traditionally undruggable targets, providing new paths to treat diseases. By using its proprietary chemoproteomics platform, IMTAC™, BridGene can screen small molecules against proteins in live cells to discover drug candidates for high value and traditionally undruggable targets. For this purpose, BridGene takes advantage of its proprietary, diverse library of tagged, drug-like small molecules. The ultimate goal is to enable breakthrough small molecule drug discovery with expanded mechanisms to treat diseases with targets previously inaccessible to small molecules. The uniqueness of BridGene's technology allows it to perform IMTAC™ screening for both covalent and non-covalent molecules, target different amino acids, and discover new targets for disease treatments by deconvoluting phenotypic screening hits. The company is advancing a diversified pipeline of first-in-class drugs for targets in multiple disease areas. For more information, visit https://www.bridgenebio.com. nnContact
SAN JOSE, Calif., March 8, 2023 /PRNewswire/ -- BridGene Biosciences, Inc., a biotechnology company that uses proprietary chemoproteomics technology to discover and develop small molecules for high-value, traditionally undruggable targets, announced that it has achieved a significant milestone in its collaboration with Takeda. The collaboration between BridGene and Takeda is based on BridGene's proprietary IMTAC™ (Isobaric Mass Tagged Affinity Characterization) chemoproteomics platform, which is used to identify targets and small molecules for Takeda to develop into therapeutic candidates for clinical development.
SAN JOSE, Calif., Aug. 1, 2022 /PRNewswire/ -- BridGene Biosciences, Inc., a biotechnology company using a proprietary chemoproteomics technology to discover and develop small molecules for high value, traditionally undruggable targets, today announced that David Sperandio, Ph.D., a medicinal chemist with more than 20 years' experience, has joined the company as the Head of Chemistry.